Lexeo Therapeutics (LXEO) Capital Expenditures (2022 - 2026)
Lexeo Therapeutics (LXEO) reported Capital Expenditures of $35000.0 for Q1 2026, down 87.89% sequentially from $289000.0 in Q3 2025.
Lexeo Therapeutics (LXEO) Capital Expenditures (2022 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 5 years of Capital Expenditures data on file, last reported at $35000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $35000.0; the trailing twelve-month figure through Mar 2026 stood at $324000.0 (changed N/A YoY), and the FY2025 full-year result was $397000.0, down 17.46% from the prior year.
- Capital Expenditures fell to $35000.0 in Q1 2026, from $289000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $289000.0 in Q3 2025 to a low of -$104000.0 in Q4 2022.
- A 5-year average of $81600.0 and a median of $57500.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures jumped 170.19% in 2023 and surged 1441.67% in 2024, its largest moves.
- Tracing LXEO's Capital Expenditures over 5 years: stood at -$104000.0 in 2022, then soared by 170.19% to $73000.0 in 2023, then climbed by 13.7% to $83000.0 in 2024, then soared by 248.19% to $289000.0 in 2025, then plunged by 87.89% to $35000.0 in 2026.
- Business Quant data shows LXEO's Capital Expenditures at $35000.0 in Q1 2026, $289000.0 in Q3 2025, and $83000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Lexeo Therapeutics | 382.38 Mn | 382.38 Mn | - | 35,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35,000.00 |
| Mar 31, 2026 | 35,000.00 |
| Sep 30, 2025 | 289,000.00 |
| Sep 30, 2025 | 289,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 213,000.00 |
| Jun 30, 2024 | 213,000.00 |
| Mar 31, 2024 | 185,000.00 |
| Mar 31, 2024 | 185,000.00 |
| Dec 31, 2023 | 73,000.00 |
| Dec 31, 2023 | 73,000.00 |
| Sep 30, 2023 | -12,000.00 |
| Sep 30, 2023 | -12,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Dec 31, 2022 | -104,000.00 |
| Dec 31, 2022 | -104,000.00 |